- NEGATIVE
Quarterly Revenue Vivimed Labs Mar-2026 Quarterly Revenue is Rs 8 Cr which is growth of -71.7% YoY.
- NEGATIVE
Quarterly Net Profit Vivimed Labs Mar-2026 Quarterly Net Profit is Rs -142 Cr which is growth of -3117.2% YoY.
Vivimed Labs quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents
Vivimed Labs quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.6 | 11.6 | 18.8 | 18.3 | 26.7 | 34.2 | 22.2 | 24.6 | 43.8 | 37.2 | 32.4 | 33 | 39.7 | ||
Operating Exp. | 144.6 | 22.9 | 20 | 18.5 | 25.1 | 34.4 | 23 | 35.7 | 59.4 | 36.3 | 35.7 | 33.3 | 203.5 | |
Operating Profit | -137 | -11.2 | -1.3 | -0.5 | -2.5 | -0.2 | -0.8 | -11.1 | -23 | 0.9 | -5.4 | -0.3 | -163.8 | |
Operating Profit Margin % | -1,814.97% | -96.47% | -7.07% | -2.99% | -10.99% | -0.52% | -3.55% | -44.95% | -63.20% | 2.38% | -17.86% | -0.88% | -412.31% | |
Depr. | 4.3 | 4.4 | 4.7 | 4.8 | 4.6 | 6.4 | 3.9 | 3.8 | 5 | 4.5 | 4.5 | 4.5 | 95.1 | |
Interest | 0.8 | 0.9 | 1.6 | 0.5 | 1.5 | 0.4 | 0.4 | 0.3 | -33.7 | 13.2 | 11.8 | 10.6 | 8.1 | |
Profit Before Tax | -142.1 | -16.6 | -7.4 | -5.5 | -4.4 | -7 | -5 | -15.1 | 13.1 | -16.7 | -19.6 | -15.4 | -266.9 | |
Tax | 1.8 | -0.6 | -2.1 | |||||||||||
Net Profit | -142.1 | -16.6 | -7.4 | -5.5 | -4.4 | -7 | -5 | -15.1 | 5.5 | -16.2 | -19.6 | -15.4 | -264.9 | |
EPS Adj. latest | -17.1 | -2 | -0.9 | -0.7 | -0.5 | -0.8 | -0.6 | -1.8 | 0.7 | -2 | -2.4 | -1.9 | -31.9 | |
Net profit TTM | -171.6 | -33.9 | -24.3 | -21.9 | -31.5 | -21.6 | -30.8 | -45.3 | -45.6 | -316 | -318.9 | -321.5 | -328 | |
Basic EPS TTM | -20.7 | -4.1 | -2.9 | -2.6 | -3.8 | -2.6 | -3.7 | -27.3 | -5.5 | -38.1 | -38.5 | -38.8 | -39.6 | |
Results PDF | ||||||||||||||
Result Notes |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Vivimed Labs competitor comparison and performance snapshot within industry
Vivimed Labs revenue mix: sales, profit, and capital employed breakups by segment
Vivimed Labs annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Annual Revenue Vivimed Labs Mar-2026 Annual Revenue is Rs 56 Cr which is growth of -47.8% YoY.
- NEGATIVE
Annual Net Profit Vivimed Labs Mar-2026 Annual Net Profit is Rs -172 Cr which is growth of -444.9% YoY.
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
-47.8%
2Y CAGR
-38%
3Y CAGR
-31.8%
5Y CAGR
-23.6%
7Y CAGR
-19.6%
10Y CAGR
-16%
Total Revenue Annual is falling faster than historical averages.
Operating Exp. Ann.
1Y CHG
74.3%
2Y CAGR
11.8%
3Y CAGR
-17.4%
5Y CAGR
2.5%
7Y CAGR
1.6%
10Y CAGR
-1.3%
Operating Expenses Annual Cr growth is higher than historical averages.
Vivimed Labs balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Total Shareholders Fund Vivimed Labs Mar-2025 Total Shareholders Fund is Rs -112 Cr which is growth of -291.8% YoY.
- NEGATIVE
Total Assets Vivimed Labs Mar-2025 Total Assets is Rs 502 Cr which is growth of -21.4% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | Mar '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
- | - | -112.2 | 58.5 | 89.4 | 133.3 | 457.3 | 524.5 | 553.9 | 572.6 | 567.4 | 560.9 | 369.6 | ||
Minority Interest Liability Ann. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
-7.5% | -4.3% | 192.6 | 187.3 | 200.9 | 243.1 | 248.7 | 240.4 | 211.9 | 243.4 | 288.3 | 296.5 | 550 | ||
0.5% | 5% | 421.8 | 393.2 | 391.2 | 415.8 | 365.8 | 330 | 301.5 | 338.5 | 399.7 | 503.1 | 445.8 | ||
Total Capital Plus Liabilities Ann. | -14.1% | -14.4% | 502.2 | 639 | 681.5 | 792.3 | 1,071.8 | 1,094.8 | 1,067.3 | 1,154.6 | 1,255.4 | 1,360.5 | 1,365.4 | |
-5.8% | -8.6% | 303.4 | 332.4 | 347 | 363.5 | 468.8 | 475 | 426.2 | 444.9 | 447.6 | 491.6 | 427.8 | ||
-11.8% | -10.8% | 359.7 | 391.2 | 405.8 | 524.7 | 630 | 636.1 | 513.7 | 532.4 | 599.5 | 579.2 | 657.8 | ||
-18.9% | -20.9% | 142.5 | 247.8 | 275.7 | 267.6 | 441.8 | 458.8 | 553.6 | 622.1 | 655.9 | 781.3 | 707.6 | ||
Total Assets Ann. | -14.1% | -14.4% | 502.2 | 639 | 681.5 | 792.3 | 1,071.8 | 1,094.8 | 1,067.3 | 1,154.6 | 1,255.4 | 1,360.5 | 1,365.4 | |
Contingent Liabilities plus Commitments Ann. | - | - | - | 182.8 | 115.7 | 123.4 | 215.6 | 220.7 | 11.5 | 55.5 | 160.9 | 236.9 | 322.7 | |
Bonus Equity Share Capital Ann. | - | - | - | |||||||||||
Non Current Investments Unquoted Book Value Ann. | - | - | - | 58.8 | 58.8 | 161.1 | 161.1 | 161.1 | 87.5 | 87.5 | 151.9 | 87.6 | 230.1 | |
Current Investments Unquoted Book Value Ann. | - | - | - |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Assets Ann.
1Y CHG
-21.4%
2Y CAGR
-14.2%
3Y CAGR
-14.1%
5Y CAGR
-14.4%
7Y CAGR
-11.2%
10Y CAGR
-9.5%
Total Assets Annual is falling faster than historical averages.
Total Current Liabilities Ann.
1Y CHG
7.3%
2Y CAGR
3.8%
3Y CAGR
0.5%
5Y CAGR
5%
7Y CAGR
3.2%
10Y CAGR
-0.6%
Total Current Liabilities Annual Cr growth is higher than historical averages.
Vivimed Labs ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Book Value Per Share Vivimed Labs Mar-2025 Book Value Per Share is -14 Rs which is growth of -647.6% YoY.
- NEUTRAL
ROE Vivimed Labs Mar-2025 ROE is 0% which is growth of 0% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | Mar '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BVSH Ann. | - | - | -13.5 | 2.5 | 6.2 | 11.5 | 50.6 | 58.7 | 62.2 | 64.8 | 64.2 | 64.5 | 227.5 | |
RoA Ann. % | - | - | -34.17% | -4.92% | -6.51% | -41.40% | -6.32% | -2.12% | -1.79% | 0.53% | 0.78% | 9.28% | 0.59% | |
ROE Ann. % | - | - | -153.70% | -86.33% | -344.12% | -16.15% | -4.78% | -3.71% | 1.15% | 1.86% | 24.16% | 2.20% | ||
ROCE Ann. % | - | - | -208.77% | -11.78% | -12.62% | -78.32% | -3.59% | 2.35% | 2.90% | 7.05% | 7.08% | 27.08% | 7.32% | |
Total Debt to Total Equity Ann. | - | - | -3.5 | 18.3 | 7.3 | 4 | 0.9 | 0.5 | 0.5 | 0.6 | 0.7 | 0.9 | 1.3 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Current Ratio Ann.
1Y CHG
-50%
2Y CAGR
-34.5%
3Y CAGR
-20.6%
5Y CAGR
-26.5%
7Y CAGR
-22.6%
10Y CAGR
-15.4%
Current Ratio Annual is falling faster than historical averages.
Vivimed Labs cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Cash From Operating Activity Vivimed Labs Mar-2026 Cash From Operating Activity is Rs 4 Cr which is growth of -22.4% YoY.
- POSITIVE
Net Cash Flow Vivimed Labs Mar-2026 Net Cash Flow is Rs -0 Cr which is growth of 74.3% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | Mar '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
-48.5% | -52.2% | 4.5 | 5.7 | -96.5 | 32.9 | 25.3 | 179.5 | 75 | 82 | 206.6 | 28.2 | -54.2 | ||
Cash from Investing Act. Ann. | - | - | -0.1 | -4.1 | 99.8 | -1.6 | -11.3 | -138.2 | 3.3 | 56.2 | -38.1 | 29.8 | -11.2 | |
Cash from Financing Act. Ann. | - | - | -4.6 | -2.5 | -5.5 | -34.7 | -13.2 | -46.4 | -91.4 | -123.2 | -174.8 | -49.6 | 58.5 | |
- | - | -0.2 | -0.9 | -2.2 | -3.4 | 0.8 | -5.1 | -13.1 | 15 | -6.4 | 8.4 | -6.8 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Cash from Operating Act. Ann.
1Y CHG
-21.1%
3Y CAGR
-48.5%
5Y CAGR
-52.2%
7Y CAGR
-33.9%
Cash from Operating Activity Annual is falling slower than historical averages.
